Applied DNA Corp (APDN) - צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים

The commercialization dynamics of LineaRx and the growth of B2B orders correlate with the share price of Applied DNA Sciences (APDN), while the quarterly EPS growth rate highlights the actual efficiency of the business. Revenues are based on the supply of DNA components and molecular tags for supply chain protection. Demand is supported by a unique bacteria-free synthesis method. The value of -109.20 reflects the metric's balance, helping to avoid overpaying at the peak of the trend.

This indicator measures the quarterly dynamics of net earnings per share, reflecting the monetization efficiency of operational processes. Analyzing the quarterly EPS change scale allows for an assessment of how the development of DNA marking and contract manufacturing of pharmaceutical components converts into actual income for Applied DNA Sciences (APDN), helping investors filter out market noise and avoid purchasing the asset at local peaks.